SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) Of The Securities Exchange Act Of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [_] Check the appropriate box: [_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) [_] Definitive Proxy Statement [X] Definitive Additional Materials [_] Soliciting Material Pursuant to Section 240.14a-12 ICN Pharmaceuticals, Inc. -------------------------------------------------------- (Name of Registrant as Specified in its Charter) N/A -------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: ------------------------------------------------------------------- (2) Aggregate number of securities to which transaction applies: ------------------------------------------------------------------- (4) Proposed maximum aggregate value of transaction: ------------------------------------------------------------------- (5) Total fee paid: ------------------------------------------------------------------- [_] Fee paid previously with preliminary materials. [_] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: ------------------------------------------------------------------- (2) Form, Schedule or Registration Statement No.: ------------------------------------------------------------------- (3) Filing Party: ------------------------------------------------------------------- (4) Date Filed: ------------------------------------------------------------------- The following is the text of an advertisement prepared by ICN Pharmaceuticals, Inc. and appearing in the Wall Street Journal on May 7, 2002: ICN LEADERSHIP CLEAR STRATEGY INDEPENDENT BOARD OF DIRECTORS |o| Developed world's second largest biotechnology drug franchise |o| Restructuring plan with tangible results |o| Successful Ribapharm IPO raised $299 million |o| Record operating results full year 2001 and first quarter 2002 versus THE DISSIDENTS NO LONG TERM PLAN NO DISCLOSED STRATEGY |x| Recent shareholders |x| Since January 2001: total of at least 195 trades in ICN, including 62 sales |x| No disclosed long term objectives |x| No experience managing a global pharmaceutical company Vote for Proven Performance. [ICN LOGO] Vote ICN Nominees. VOTE THE GOLD PROXY CARD ---- If you have any questions or need assistance voting your shares, please call: MORROW & CO., INC. Call 1-800-607-0088